Which pharmaceutical companies in China produce ibrutinib/ibrutinib?

Ibrutinib/Ibrutinib, as an important targeted therapy drug, has also received widespread attention and application in China. The original drug is already on the market in China and is sold in some hospitals and other places. Regarding pharmaceutical companies producing domestic generic versions of ibrutinib in China, although the number is limited, they may already exist.

First of all, it needs to be made clear that the original manufacturer of ibrutinib is the United StatesPharmacyclics LLC, which is the pharmaceutical company that originally developed and produced ibrutinib. However, in China, the production and sales of ibrutinib are usually carried out through licensing or cooperation. Currently, among the pharmaceutical companies in China that have been authorized to produce and sell ibrutinib, the drug produced by Simcere Pharmaceutical Co., Ltd. is in the process of obtaining relevant approvals from the State Food and Drug Administration, providing Chinese patients with more treatment options while ensuring that the ingredients are consistent with the original drug.

Ibrutinib/Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenstrom's macroglobulinemia (WM), and chronic graft-versus-host disease (cGVHD). Clinical in vitro studies have shown that CLL cell apoptosis can be induced even in the presence of pro-survival factors. Inhibition of CLL cell survival and proliferation as well as impairment of cell migration and reduced secretion of chemokines such as CCL3 and CCL4 have also been reported. This latter effect has been shown to produce degeneration in xenograft mouse models.

The original ibrutinib drug is marketed in China in the form of capsules and is reimbursed by Class B medical insurance, but only for patients who meet the indications. The common specification is 140mg*90 capsules, and the price per box is about RMB 10,000. The price of domestic generic drugs is unclear.